Alaunos Therapeutics, Inc.
Income Statement
| Line Item | FY2016 | FY2012 | FY2011 |
|---|---|---|---|
| Revenue | $6.9M | $800.0K | $667.0K |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $157.8M | $83.4M | $57.1M |
| SG&A Expense | $14.4M | $19.5M | $15.0M |
| Operating Income | $-165.3M | $-102.2M | $-71.4M |
| Operating Margin | -2,409.4% | -12,771.1% | -10,704.6% |
| Interest Expense | — | — | — |
| Pretax Income | — | — | — |
| Income Tax Expense | — | — | — |
| Net Income | $-165.3M | $-96.1M | $-63.8M |
| Net Margin | -2,409.2% | -12,016.5% | -9,561.9% |
| EPS (Basic) | $-1.32 | $-1.22 | $-0.97 |
| EPS (Diluted) | $-1.32 | $-1.22 | $-0.97 |
| Shares Outstanding (Basic) | 130.4M | 83.2M | 69.2M |
| Shares Outstanding (Diluted) | 130.4M | 83.2M | 69.2M |
| Dividends Per Share | — | — | — |